Merck has received an expanded indication from the U.S. Food and Drug Administration for Winrevair (sotatercept-csrk), bolstering its role in the treatment of adults with pulmonary arterial hypertension (PAH). This regulatory milestone was based on new evidence from the Phase 3 ZENITH study, a large-scale, double-blind clinical trial enrolling patients at high risk of poor outcomes due to PAH.
The ZENITH trial findings demonstrated that adding Winrevair to established background therapy led to improvements in exercise capacity and World Health Organization (WHO) functional class, reflecting better day-to-day functioning and endurance for patients. Crucially, Winrevair also produced a marked reduction in the risk of major clinical events—including hospitalization for PAH, the need for lung transplantation, and death—versus placebo. The study’s robust outcomes prompted the trial’s independent monitoring board to recommend early termination due to overwhelming benefit.
Winrevair operates as an activin signaling inhibitor, an innovative class of therapy that helps rebalance vascular cell growth and pressure within the lungs. Safety outcomes in the ZENITH study aligned with previously reported trials, and no unexpected signals emerged.
This updated approval means that Winrevair is now positioned to address more severe complications of PAH—a significant advancement for patients who remain at risk despite conventional treatments. Merck’s achievement solidifies Winrevair’s status as a cornerstone therapy as the company aims to address critical gaps in PAH care.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!